(CercleFinance.com) – The Swiss ophthalmological group Alcon has unveiled first quarter results up and above expectations, which leads it to consider an annual profit at the top of its forecasts.
The former Novartis subsidiary announced last night that it generated sales up 7% to $2.3 billion in the first three months of the year, including 11% growth at constant exchange rates.
Its operating margin also improved from 11.3% to 11.5% over the quarter, while its core earnings per share (EPS) increased from 68 to 70 cents. one year to the next.
In its press release, the Basel company indicated that it now plans to generate 2023 EPS at the upper end of the range of 2.55 to 2.65 dollars that it had initially set itself as a target.
For UBS analysts, this optimism should reassure the market about the company’s ability to achieve its ambitions for 2023, but also its outlook for 2025 or 2027.
‘This should lead to an upward revision of the medium-term forecasts established by the market as well as a revaluation of the title from our point of view’, indicates the research department.
Listed on the Zurich Stock Exchange, Alcon shares jumped 7.4% in the wake of this publication.
Copyright (c) 2023 CercleFinance.com. All rights reserved.